Coca-Cola, Credit Suisse and Philips rise premarket; Bed Bath & Beyond falls

  • Stock Market News
Coca-Cola, Credit Suisse and Philips rise premarket; Bed Bath & Beyond falls

By Peter Nurse -- Stocks in focus in premarket trade on Monday, April 24th. Please refresh for updates.

  • Bed Bath & Beyond (NASDAQ: BBBY ) stock slumped over 35% after the embattled home goods retailer filed for bankruptcy protection, following years of underperformance.

  • Coca-Cola (NYSE: KO ) stock rose 1.4% after the soft drinks giant beat expectations for quarterly revenue, as demand for its produce remained resilient in the face of multiple price increases.

  • Philips (NYSE: PHG ) ADRs climbed 13.2% after the Dutch health technology company reported much better than expected first quarter results and said it had set aside around $630 million related to lawsuits over its recall of respiratory devices.

  • Credit Suisse (SIX: CSGN ) (NYSE: CS ) ADRs rose 1.9% after the Swiss lender, in the process of being acquired by rival UBS (NYSE: UBS ), up 1.6%, shelved plans to purchase Michael Klein’s investment firm following $68 billion of outflows last quarter.

  • PPG Industries (NYSE: PPG ) stock rose 1.8% after JPMorgan upgraded its stance on the industrial coatings supplier to ‘overweight’ from ‘neutral’ following last week’s strong quarterly earnings and upbeat full-year guidance.

  • Comcast (NASDAQ: CMCSA ) stock fell 0.2% after the weekend departure of Jeff Shell, the CEO of unit NBCUniversal, following a complaint of an inappropriate relationship with a woman in the company.

  • First Solar (NASDAQ: FSLR ) stock fell 2.5% after Citigroup downgraded the solar panel manufacturer to ‘sell’ from ‘neutral’, citing uncertainty surrounding the company’s long-term outlook for margins and growth.

  • Kingsoft Cloud (NASDAQ: KC ) stock fell 5.9% after Goldman Sachs downgraded the Chinese software company to ‘sell’ from ‘neutral’ with the stock up nearly 75% year to date.

  • Foghorn Therapeutics (NASDAQ: FHTX ) stock fell around 22.9% after the FDA placed a partial clinical hold on the trial of the company’s key cancer drug.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles